Amylyx Pharmaceuticals, Inc.
AMLX$518M
Small CapNASDAQPharmaceutical Preparations🇺🇸North AmericaCAMBRIDGE123 employees
Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024.
Drugs in Pipeline
2
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
Aug 6, 2026
6wMarket Overview
Stock performance and key metrics
AMLX News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply